What is tibolone (Livial)?

Br J Obstet Gynaecol. 1998 Aug;105(8):904-11.

A double-blind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms.

Authors:

Hammar M,Christau S,Nathorst-Boos J,Rud T,Garre K.

Department of Obstetrics and Gynaecology, University Hospital, Linkoping, Sweden.

Objectives:

To compare the effects of two postmenopausal regimens on menopausal symptoms, bleeding episodes, side effects and acceptability.

Design:

Double-blind, randomised controlled trial.

Setting:

Twenty-nine sites in Denmark, nine in Norway and six in Sweden.

Participants:

Four hundred and thirty-seven postmenopausal women with menopausal complaints. None of these women had had a hysterectomy.

Interventions:

Daily treatment with tibolone 2.5 mg (n = 218) or 17beta-oestradiol 2 mg plus norethisterone acetate 1 mg (E2/NETA) (n = 219).

Settings, Design and Main Outcome Measures:

Hot flushes, sweating episodes, vaginal dryness, assessment of sexual life and bleeding patterns; at baseline and after 4, 12, 24 and 48 weeks.

Results:

Treatment with either preparation significantly reduced mean scores for hot flushes, sweating episodes and vaginal dryness. The overall discontinuation rate was 28% (tibolone 25%, E2/NETA 31%; P = 0.14), mostly during the first six months. There was a markedly lower cumulative incidence of bleeding or spotting episodes with tibolone compared with E2/NETA (P< 0.0001), mainly during the first six treatment cycles.

Conclusions:

Both tibolone and E2/NETA effectively alleviate menopausal symptoms. However, tibolone caused significantly fewer bleeding or spotting episodes, which were reflected by lower overall rates of bleeding, as well as lower drop-out rates due to bleeding.

Please click on the required question.